Myeloproliferative Disorders (Myeloproliferative Disorder)

Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Also Known As:
Myeloproliferative Disorder; Disorder, Myeloproliferative; Disorders, Myeloproliferative
Networked: 1177 relevant articles (44 outcomes, 88 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Thrombocytosis (Thrombocythemia)
2. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
3. Essential Thrombocythemia
4. Lymphoma (Lymphomas)
5. Polycythemia Vera


1. Tefferi, Ayalew: 23 articles (03/2010 - 01/2003)
2. Gilliland, D Gary: 16 articles (01/2007 - 01/2002)
3. Cross, Nicholas C P: 15 articles (01/2008 - 01/2002)
4. Kantarjian, Hagop: 10 articles (02/2008 - 09/2002)
5. Verstovsek, Srdan: 9 articles (09/2013 - 09/2003)
6. Vainchenker, William: 9 articles (02/2010 - 04/2005)
7. Cortes, Jorge: 9 articles (02/2008 - 10/2002)
8. Reiter, Andreas: 8 articles (01/2012 - 09/2005)
9. Giles, Francis: 8 articles (11/2007 - 09/2002)
10. Kreipe, Hans: 8 articles (01/2007 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myeloproliferative Disorders:
1. Interferon-alpha (Interferon Alfa)FDA Link
2. anagrelide (Agrylin)FDA LinkGeneric
3. imatinib (Gleevec)FDA Link
4. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
5. Hydroxyurea (Hydrea)FDA LinkGeneric
6. Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
7. Messenger RNA (mRNA)IBA
8. ranimustineIBA
9. Phosphotransferases (Kinase)IBA
10. Janus Kinase 2IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Splenectomy
3. Bone Marrow Transplantation (Transplantation, Bone Marrow)
4. Hematopoietic Stem Cell Transplantation
10/01/2011 - "The results showed that (1) out of 46 newly diagnosed as chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, 22 cases were diagnosed as CML, the FISH detection showed all positive (100%), while cytogenetic test showed 86.4% (19/22) positive, in the other 24 patients who were diagnosed as other chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, BCR/ABL fusion gene all were be detected as negative 100% by FISH, while the cytogenetic test of bone marrow in 3 cases supported the diagnosis of CML, and the diagnosis of myelodysplastic disorder in 1 case; (2) in 3 out of 7 acute lymphocytic leukemia cases the BCR/ABL fusion gene could not be detected by FISH; (3) the BCR/ABL fusion gene could be detected by FISH in 2 cases of CML received allogeneic hematopoietic stem cell transplantation, with abnormal threshold 6.5% and 1.2% respectively. "
06/01/2007 - "Juvenile myelomonocytic leukemia (JMML) is a rapidly fatal myeloproliferative disorder of early childhood for which no effective treatment other than hematopoietic stem cell transplantation is currently available. "
10/01/2003 - "Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes."
01/01/2011 - "Children with Noonan syndrome (NS) are at increased risk of developing juvenile myelomonocytic leukemia (JMML) or a myeloproliferative disorder associated with NS (MPD/NS) resembling JMML in the first weeks of life; whereas JMML is an aggressive disorder requiring hematopoietic stem cell transplantation, MPD/NS may resolve without treatment and cases with spontaneous remission have also been reported. "
10/01/2011 - "The conventional cytogenetic test and detection of BCR/ABL fusion gene by FISH for bone marrow of patients with newly diagnosed chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, acute lymphocytic leukemia and chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation were carried out. "
5. Radiotherapy